SEK 668
Key Takeaways
Risk factor
Very vulnerable to price shocks
Profitability factor
Excellent growth
About
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity;...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of CAMX.ST is 826 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
